奥扎格雷和低分子肝素治疗糖尿病下肢血管病变的效果比较  

Comparison of ozagrel and low molecular weight heparin in the treatment of diabetic lower extremity vascular disease

作　　者：叶军[1] 章容[1] 汪运生[1] 戴武[1] 曹永红[1] 刘燕[1] 张苏皖[1] 

机构地区：[1]安徽合肥市第二人民医院内分泌科,230011

出　　处：《中国临床保健杂志》2014年第5期511-512,共2页Chinese Journal of Clinical Healthcare

摘　　要：目的比较奥扎格雷和低分子肝素治疗糖尿病下肢血管病变(LEDDP)的疗效及安全性。方法64例糖尿病下肢血管病变患者随机分为两组,在常规治疗基础上,分别予以常规剂量奥扎格雷钠和低分子肝素钙抗凝治疗,比较治疗前后腘动脉收缩期峰值血流速度(PSV)及部分活化凝血酶原时间(APTT)、凝血酶原时间(PT)变化。结果两组腘动脉PSV治疗前后差值均差异有统计学意义(P<0.05),但改善的幅度不一致,低分子肝素组效果更佳,与奥扎格雷组比较差异有统计学意义;两组治疗前后APTT、PT差值差异无统计学意义。结论奥扎格雷和低分子肝素抗凝治疗LEDDP均有一定疗效,安全性良好,其中低分子肝素改善PSV效果更佳。Objective To compare the effect and safety of Ozagrel and low molecular weight heparin in the treatment of diabetic lower extremity vascular disease（ LEDDP） Methods A total of 64 cases with diabetic lower extremity vascular disease were collected and randomly divided into two groups. Based on the conventional treatment,The patients in the two groups received routine doses of low molecular weight heparin and ozagrel anticoagulant for 14 days. Results There were statistically significant difference in popliteal artery peak systolic velocity（ PSV） of two groups before and after treatment（ P〈 0. 05）,while the effects showed better in low molecular weight heparin group compared with ozagrel group. There were no significant difference in ctivated partial thromboplastin time（ APTT） and prothrombin time（ PT） before and after treatment. Conclusion The low molecular weight heparin or ozagrel anticoagulant therapy is effective and safety in the treatment of LEDDP,and LMWH show a better improvement in PSV.

关 键 词：糖尿病血管病变 肝素 低分子量 抗凝药 血流速度 

分 类 号：R587.2[医药卫生—内分泌]